A Message From ISSM President Luca Incrocci
ISSM Treasurer Annamaria Giraldi: Learn More About Female Sexual Dysfunction at the World Meeting
Dear members and colleagues of ISSM,
We are approaching the end of the year, one year full of activities for ISSM and in the field of sexual medicine in general.
I am glad to see so many committed members of ISSM and its affiliated societies organize educational activities, courses, meetings in several parts of the world to promote sexual medicine.
The ESSM school of Sexual Medicine (Budapest, October 27-November 5) was again a huge success with 43 attendees from Europe, Asia, Africa, USA, Australia, Middle East and South America. ISSM supported, same as in the previous years, 10 participants from less developed countries to attend the school.
The SASSM organized a course in Bangladesh (Dhaka, September 23-25) attended by 64 people (psychiatrists, dermatologists, urologists, endocrinologists and gynecologists).
APSSM organized a one-day crash course on sexual medicine during the VSSM (Vietnamese Society for Sexual Medicine, Vung Tau, November 25).
ISSM participated, through the Developing Countries Cte, in several meetings, such as PAUSA (Zimbabwe, March), SIU (Lisbon, October) and MESSM (September).
Please click here to see more of Prof. Incrocci's message, including information on the ISSM's strategic plan, the World Meeting on Sexual Medicine, and upcoming elections for the ISSM Board of Directors.
Happy holidays to all!
Aromatase Inhibitors Associated with HSDD, Fecal Incontinence
Are you interested in learning more about female sexual dysfunction? You'll have many opportunities to do so at next year's World Meeting on Sexual Medicine, as ISSM Treasurer Annamaria Giraldi explains in her video invitation.
Join your colleagues in Lisbon February 28 - March 3, 2018! You'll find all the details about the meeting here.
Female breast cancer survivors who take aromatase inhibitors (AIs) often have hypoactive sexual desire disorder (HSDD) and experience fecal incontinence, even 10 years after their cancer diagnosis, experts report.
Their study, published online in October in the Journal of Sexual Medicine, involved 625 Australian women with a median age of 65. About 85% had been diagnosed with hormone receptor positive breast cancer approximately 10 years earlier. At the time of the study, 13% of the women took AIs or tamoxifen.
HSDD - low libido accompanied by distress - was more common in the women taking AIs, affecting 55% of that group and 38% of those who did not take AIs.
About 30% of AI users and 16% of non-AIs experienced fecal incontinence.
Please see more details on this study here.
All of us at the ISSM would like to wish you and your families a very happy, healthy, and prosperous new year!